Chronic Lymphocytic Leukemia

New Indication: Pirtobrutinib in CLL

2023-11-20

  • Study

    Open-label, multi-center Phase 1/2 study (BRUIN)
    Relapse/Refractory CLL/SLL who had previously received a BTK inhibitor
    Pirtobrutinib (n=317)


  • Efficacy

    ORR:73.3% [67.3-78.7]
    mPFS. 19.6 mos [16.9-22.1]


  • Safety

    Grade3: Neutropneia (26.8%), infections (28.1%), anemia (8.8%)


    • N Engl J Med 2023; 389:33-44

    Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia

    http://doi.org/10.1056/NEJMoa2300696

    Reviewed by Elvin Chalabiyev, MD on Nov 20, 2023